The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells

Previous studies have suggested that histone methylation can modulate carcinogenesis and cancer progression. For instance, the histone methyltransferase SET and MYND domain containing 2 (SMYD2) is overexpressed in several types of cancer tissue. The aim of the present study was to determine whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Machiko, Sone, Kenbun, Oda, Katsutoshi, Hamamoto, Ryuji, Kaneko, Syuzo, Oki, Shinya, Kukita, Asako, Kawata, Akira, Honjoh, Harunori, Kawata, Yoshiko, Kashiyama, Tomoko, Sato, Masakazu, Taguchi, Ayumi, Miyamoto, Yuichiro, Tanikawa, Michihiro, Tsuruga, Tetsushi, Nagasaka, Kazunori, Wada-Hiraike, Osamu, Osuga, Yutaka, Fujii, Tomoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471656/
https://www.ncbi.nlm.nih.gov/pubmed/32934721
http://dx.doi.org/10.3892/ol.2020.12014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471656/
https://www.ncbi.nlm.nih.gov/pubmed/32934721
http://dx.doi.org/10.3892/ol.2020.12014

Ejemplares similares